{"disease":{"id":"progesterone-receptor-positive","name":"progesterone receptor positive"},"drugs":{"marketed":[{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01275677","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3270,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00785291","title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03723928","title":"S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":739,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT04086875","title":"A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":332,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT00390455","title":"Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02526498","title":"Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT04504916","title":"A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02398773","title":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":99,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02015559","title":"Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT00338728","title":"Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02668666","title":"Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Oana Danciu, MD","has_results":true},{"nct_id":"NCT02957968","title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Virginia Commonwealth University","has_results":true},{"nct_id":"NCT02152943","title":"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06538389","title":"High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03691493","title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT02648477","title":"Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT06401889","title":"Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03359954","title":"Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03870399","title":"Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"AC Camargo Cancer Center","has_results":false},{"nct_id":"NCT06264921","title":"A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"NiKang Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02186470","title":"Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03523195","title":"Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03132467","title":"Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02760030","title":"Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01846091","title":"Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02219789","title":"Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03128619","title":"Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02269670","title":"Phase II Study of Everolimus Beyond Progression","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT03477396","title":"Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT03070002","title":"Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT03666819","title":"Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT03091842","title":"Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03377101","title":"Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03042897","title":"Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Southern California","has_results":false}],"total":36},"guidelines":[],"source":"Drug Landscape verified database"}